Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:cyclobutanes
go back to main search page
Accession:CHEBI:156473 term browser browse the term
Definition:Cyclobutane and its derivatives formed by substitution.
Synonyms:xref_mesh: MESH:D003503


show annotations for term's descendants           Sort by:
 
cyclobutanes term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO Cyclobutanes results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr 1:171,213,934...171,218,845
Ensembl chr 1:171,213,970...171,220,701
JBrowse link
carboplatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A decreases expression ISO Carboplatin results in decreased expression of ABCB1 mRNA; Carboplatin results in decreased expression of ABCB1 protein CTD PMID:27692344 NCBI chr 5:8,567,091...8,748,575
Ensembl chr 5:8,660,077...8,748,575
JBrowse link
G Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 decreases expression ISO Carboplatin results in decreased expression of ABCB4 mRNA CTD PMID:18172885 NCBI chr 5:8,893,614...8,959,226
Ensembl chr 5:8,893,717...8,959,231
JBrowse link
G Abcc1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 decreases expression ISO Carboplatin results in decreased expression of ABCC1 mRNA; Carboplatin results in decreased expression of ABCC1 protein CTD PMID:27692344 NCBI chr16:14,361,453...14,474,878
Ensembl chr16:14,361,558...14,475,737
JBrowse link
G Abcc2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 decreases expression ISO Carboplatin results in decreased expression of ABCC2 mRNA; Carboplatin results in decreased expression of ABCC2 protein CTD PMID:27692344 NCBI chr19:43,782,308...43,838,332
Ensembl chr19:43,782,192...43,840,740
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 (Junior blood group) decreases expression ISO Carboplatin results in decreased expression of ABCG2 mRNA; Carboplatin results in decreased expression of ABCG2 protein CTD PMID:27692344 NCBI chr 6:58,584,491...58,692,451
Ensembl chr 6:58,584,523...58,695,676
JBrowse link
G Acvr1c activin A receptor, type IC increases response to substance ISO ACVR1C results in increased susceptibility to Carboplatin CTD PMID:21224400 NCBI chr 2:58,267,453...58,357,896
Ensembl chr 2:58,267,453...58,357,895
JBrowse link
G Akr1b3 aldo-keto reductase family 1, member B3 (aldose reductase) increases expression ISO Carboplatin results in increased expression of AKR1B1 mRNA CTD PMID:18172885 NCBI chr 6:34,303,930...34,317,489
Ensembl chr 6:34,302,434...34,317,478
JBrowse link
G Akt1 thymoma viral proto-oncogene 1 multiple interactions EXP Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein] CTD PMID:18483861 NCBI chr12:112,653,821...112,674,884
Ensembl chr12:112,653,821...112,674,884
JBrowse link
G Alas2 aminolevulinic acid synthase 2, erythroid decreases expression ISO Carboplatin results in decreased expression of ALAS2 mRNA CTD PMID:21296123 NCBI chr  X:150,547,417...150,570,622
Ensembl chr  X:150,547,375...150,570,638
JBrowse link
G Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 affects response to substance ISO ALDH1A1 protein affects the susceptibility to Carboplatin CTD PMID:18854779 NCBI chr19:20,492,583...20,643,463
Ensembl chr19:20,492,715...20,643,465
JBrowse link
G Aldh3a1 aldehyde dehydrogenase family 3, subfamily A1 affects response to substance ISO ALDH3A1 protein affects the susceptibility to Carboplatin CTD PMID:18854779 NCBI chr11:61,208,510...61,218,418
Ensembl chr11:61,207,537...61,218,421
JBrowse link
G Anxa4 annexin A4 decreases response to substance
affects localization
multiple interactions
ISO ANXA4 protein results in decreased susceptibility to Carboplatin
Carboplatin affects the localization of ANXA4 protein
ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin]
CTD PMID:24150977 NCBI chr 6:86,736,840...86,793,634
Ensembl chr 6:86,736,840...86,793,584
JBrowse link
G Arfgef1 ADP-ribosylation factor guanine nucleotide-exchange factor 1(brefeldin A-inhibited) increases response to substance ISO ARFGEF1 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr 1:10,137,507...10,232,670
Ensembl chr 1:10,137,571...10,232,670
JBrowse link
G Atp1a1 ATPase, Na+/K+ transporting, alpha 1 polypeptide decreases expression ISO Carboplatin results in decreased expression of ATP1A1 mRNA CTD PMID:18172885 NCBI chr 3:101,576,219...101,604,707
Ensembl chr 3:101,576,219...101,604,684
JBrowse link
G Atp7a ATPase, Cu++ transporting, alpha polypeptide affects localization
multiple interactions
ISO Carboplatin affects the localization of ATP7A protein
[MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Carboplatin; ATP7A protein promotes the reaction [ANXA4 protein results in decreased susceptibility to Carboplatin]
CTD PMID:24038379 PMID:24150977 NCBI chr  X:106,027,224...106,128,161
Ensembl chr  X:106,027,276...106,124,926
JBrowse link
G Atp7b ATPase, Cu++ transporting, beta polypeptide multiple interactions ISO ATP7B protein binds to and results in increased metabolism of Carboplatin CTD PMID:23751120 NCBI chr 8:21,992,783...22,060,074
Ensembl chr 8:21,992,785...22,060,305
JBrowse link
G Bax BCL2-associated X protein decreases expression
multiple interactions
ISO Carboplatin results in decreased expression of BAX mRNA
Carboplatin results in increased cleavage of and results in increased expression of BAX protein
CTD PMID:15131059 PMID:15576332 NCBI chr 7:45,461,695...45,466,903
Ensembl chr 7:45,461,697...45,466,898
JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 decreases expression ISO Carboplatin results in decreased expression of BCL2 mRNA; Carboplatin results in decreased expression of BCL2 protein CTD PMID:9664115 PMID:15576332 PMID:15996812 PMID:17404015 NCBI chr 1:106,538,176...106,714,290
Ensembl chr 1:106,538,178...106,714,274
JBrowse link
G Bcl2l1 BCL2-like 1 decreases expression
multiple interactions
EXP
ISO
Carboplatin results in decreased expression of BCL2L1 protein
Acetylcysteine inhibits the reaction [Carboplatin results in decreased expression of BCL2L1 protein]
CTD PMID:18483861 NCBI chr 2:152,758,732...152,833,803
Ensembl chr 2:152,780,668...152,831,728
JBrowse link
G Bcl2l12 BCL2-like 12 (proline rich) increases expression ISO Carboplatin results in increased expression of BCL2L12 mRNA CTD PMID:15576332 NCBI chr 7:44,991,222...44,997,638
Ensembl chr 7:44,991,222...44,998,712
JBrowse link
G Becn1 beclin 1, autophagy related decreases expression
multiple interactions
ISO Carboplatin results in decreased expression of BECN1 protein
Carboplatin promotes the reaction [Chloroquine results in decreased expression of BECN1 protein]; Chloroquine promotes the reaction [Carboplatin results in decreased expression of BECN1 protein]
CTD PMID:27692344 NCBI chr11:101,288,258...101,302,286
Ensembl chr11:101,285,952...101,302,286
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases response to substance ISO BIRC2 protein results in decreased susceptibility to Carboplatin CTD PMID:10815900 NCBI chr 9:7,818,226...7,837,131
Ensembl chr 9:7,818,227...7,837,064
JBrowse link
G Blmh bleomycin hydrolase decreases expression ISO Carboplatin results in decreased expression of BLMH mRNA CTD PMID:18172885 NCBI chr11:76,945,656...76,987,389
Ensembl chr11:76,924,809...76,987,379
JBrowse link
G Brca1 breast cancer 1, early onset decreases activity ISO Carboplatin results in decreased activity of BRCA1 protein CTD PMID:20878461 NCBI chr11:101,488,761...101,551,955
Ensembl chr11:101,488,764...101,551,955
JBrowse link
G Camkk2 calcium/calmodulin-dependent protein kinase kinase 2, beta affects response to substance ISO CAMKK2 protein affects the susceptibility to Carboplatin CTD PMID:28634229 NCBI chr 5:122,718,380...122,779,522
Ensembl chr 5:122,731,170...122,779,409
JBrowse link
G Canx calnexin decreases expression ISO Carboplatin results in decreased expression of CANX mRNA CTD PMID:18172885 NCBI chr11:50,293,957...50,325,673
Ensembl chr11:50,293,961...50,325,673
JBrowse link
G Casp2 caspase 2 decreases expression ISO Carboplatin results in decreased expression of CASP2 mRNA CTD PMID:18172885 NCBI chr 6:42,264,902...42,282,508
Ensembl chr 6:42,264,985...42,282,508
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases expression
ISO
EXP
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein]; Carboplatin results in increased cleavage of and results in increased activity of CASP3 protein; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein]
Carboplatin results in increased expression of CASP3 protein
Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]
Carboplatin results in increased expression of CASP3 mRNA
CTD PMID:15576332 PMID:16275998 PMID:18483861 PMID:20368269 PMID:22302033 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689
JBrowse link
G Casp7 caspase 7 increases activity
multiple interactions
ISO Carboplatin results in increased activity of CASP7 protein
palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]
CTD PMID:22302033 NCBI chr19:56,396,833...56,442,348
Ensembl chr19:56,397,129...56,442,344
JBrowse link
G Casp9 caspase 9 increases activity
decreases expression
multiple interactions
increases expression
ISO
EXP
Carboplatin results in increased activity of CASP9 protein
Carboplatin results in decreased expression of CASP9 mRNA
Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]
CTD PMID:15576332 PMID:15996812 PMID:17404015 PMID:18483861 NCBI chr 4:141,793,612...141,815,978
Ensembl chr 4:141,793,612...141,815,976
JBrowse link
G Cat catalase decreases activity
decreases expression
multiple interactions
ISO Carboplatin results in decreased activity of CAT protein
Carboplatin results in decreased expression of CAT protein
Carboplatin results in decreased expression of and results in decreased activity of CAT protein
CTD PMID:11124453 PMID:15109710 PMID:15225673 NCBI chr 2:103,453,904...103,485,153
Ensembl chr 2:103,453,849...103,485,160
JBrowse link
G Cd274 CD274 antigen decreases expression ISO Carboplatin results in decreased expression of CD274; Carboplatin results in decreased expression of CD274 protein CTD PMID:21765211 PMID:27692344 NCBI chr19:29,362,107...29,388,095
Ensembl chr19:29,367,455...29,388,095
JBrowse link
G Cd44 CD44 antigen decreases expression ISO Carboplatin results in decreased expression of CD44 mRNA CTD PMID:18172885 NCBI chr 2:102,811,141...102,901,669
Ensembl chr 2:102,811,141...102,901,665
JBrowse link
G Cdc25b cell division cycle 25B decreases expression ISO Carboplatin results in decreased expression of CDC25B mRNA CTD PMID:21296123 NCBI chr 2:131,186,436...131,198,511
Ensembl chr 2:131,186,949...131,198,497
JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Carboplatin results in decreased expression of CDC42 mRNA CTD PMID:18172885 NCBI chr 4:137,319,696...137,357,759
Ensembl chr 4:137,319,696...137,357,720
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) increases expression ISO Carboplatin results in increased expression of CDKN1A protein
Carboplatin results in increased expression of CDKN1A mRNA
CTD PMID:9664115 PMID:18172885 NCBI chr17:29,090,979...29,100,722
Ensembl chr17:29,090,976...29,100,727
JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 increases expression ISO Carboplatin results in increased expression of CITED2 mRNA CTD PMID:18172885 NCBI chr10:17,723,228...17,725,674
Ensembl chr10:17,723,218...17,725,674
JBrowse link
G Clu clusterin decreases expression ISO Carboplatin results in decreased expression of CLU mRNA CTD PMID:18172885 NCBI chr14:65,968,483...65,981,548
Ensembl chr14:65,968,483...65,981,547
JBrowse link
G Cops5 COP9 signalosome subunit 5 increases response to substance ISO COPS5 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr 1:10,024,600...10,038,159
Ensembl chr 1:10,024,601...10,038,168
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO Acetylcysteine inhibits the reaction [Carboplatin results in increased expression of CYCS protein]; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein] CTD PMID:18483861 NCBI chr 6:50,562,563...50,566,569
Ensembl chr 6:50,562,563...50,566,538
JBrowse link
G Dct dopachrome tautomerase decreases response to substance ISO DCT protein results in decreased susceptibility to Carboplatin CTD PMID:15897911 NCBI chr14:118,012,790...118,052,246
Ensembl chr14:118,012,790...118,052,244
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO Carboplatin results in increased expression of DDIT3 mRNA CTD PMID:18172885 NCBI chr10:127,290,793...127,296,291
Ensembl chr10:127,290,774...127,296,288
Ensembl chr10:127,290,774...127,296,288
JBrowse link
G Dpyd dihydropyrimidine dehydrogenase multiple interactions ISO PCNA mRNA affects the reaction [DPYD mRNA affects the susceptibility to Carboplatin] CTD PMID:16685392 NCBI chr 3:118,562,109...119,432,924
Ensembl chr 3:118,562,129...119,432,924
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2, subunit 1 alpha affects phosphorylation ISO Carboplatin affects the phosphorylation of EIF2S1 protein CTD PMID:29053414 NCBI chr12:78,862,072...78,887,010
Ensembl chr12:78,861,819...78,887,010
JBrowse link
G Epcam epithelial cell adhesion molecule multiple interactions ISO [Paclitaxel co-treated with Carboplatin] results in increased expression of EPCAM protein CTD PMID:12695858 NCBI chr17:87,635,979...87,651,127
Ensembl chr17:87,635,979...87,651,129
JBrowse link
G Epo erythropoietin increases expression ISO Carboplatin results in increased expression of EPO protein CTD PMID:17891399 NCBI chr 5:137,483,020...137,485,816
Ensembl chr 5:137,483,020...137,533,242
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] CTD PMID:16446318 NCBI chr11:98,412,484...98,437,716
Ensembl chr11:98,412,470...98,437,716
JBrowse link
G Fas Fas (TNF receptor superfamily member 6) increases expression ISO Carboplatin results in increased expression of FAS mRNA CTD PMID:15576332 NCBI chr19:34,290,647...34,327,775
Ensembl chr19:34,290,666...34,327,772
JBrowse link
G Fshb follicle stimulating hormone beta increases expression ISO Carboplatin results in increased expression of FSHB protein CTD PMID:8776818 NCBI chr 2:107,055,986...107,059,651
Ensembl chr 2:107,056,140...107,059,656
JBrowse link
G Gsr glutathione reductase decreases activity ISO Carboplatin results in decreased activity of GSR protein CTD PMID:11124453 NCBI chr 8:33,653,238...33,698,162
Ensembl chr 8:33,652,523...33,698,163
JBrowse link
G Gstp1 glutathione S-transferase, pi 1 affects response to substance ISO GSTP1 gene affects the susceptibility to Carboplatin CTD PMID:12360105 NCBI chr19:4,035,411...4,037,912
Ensembl chr19:4,035,407...4,037,985
JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions
ISO Carboplatin results in increased expression of H2AX protein
palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]
CTD PMID:22302033 NCBI chr 9:44,334,715...44,336,077
Ensembl chr 9:44,334,694...44,336,077
JBrowse link
G Hax1 HCLS1 associated X-1 multiple interactions ISO Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein] CTD PMID:18483861 NCBI chr 3:89,995,446...89,998,716
Ensembl chr 3:89,995,446...89,998,780
JBrowse link
G Hbb-b1 hemoglobin, beta adult major chain decreases expression ISO Carboplatin results in decreased expression of HBB mRNA CTD PMID:21296123
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
decreases response to substance
decreases expression
EXP
ISO
HMOX1 protein inhibits the reaction [Carboplatin results in increased activity of NFATC4]
Carboplatin results in increased expression of HMOX1 mRNA
HMOX1 protein results in decreased susceptibility to Carboplatin
Carboplatin results in decreased expression of HMOX1 mRNA
CTD PMID:18172885 PMID:20368269 PMID:21198546 PMID:26260164 NCBI chr 8:75,093,618...75,100,593
Ensembl chr 8:75,093,621...75,100,589
JBrowse link
G Hsd17b4 hydroxysteroid (17-beta) dehydrogenase 4 decreases expression ISO Carboplatin results in decreased expression of HSD17B4 mRNA CTD PMID:18172885 NCBI chr18:50,128,201...50,196,270
Ensembl chr18:50,128,201...50,196,269
JBrowse link
G Hspa1a heat shock protein 1A increases expression ISO Carboplatin results in increased expression of HSPA1A mRNA CTD PMID:18172885 NCBI chr17:34,969,359...34,972,156
Ensembl chr17:34,969,190...34,972,156
JBrowse link
G Hspa1b heat shock protein 1B increases expression ISO Carboplatin results in increased expression of HSPA1B mRNA CTD PMID:18172885 NCBI chr17:34,956,429...34,959,238
Ensembl chr17:34,956,436...34,959,238
JBrowse link
G Hspa5 heat shock protein 5 decreases expression ISO Carboplatin results in decreased expression of HSPA5 mRNA CTD PMID:18172885 NCBI chr 2:34,772,090...34,776,529
Ensembl chr 2:34,771,970...34,777,547
JBrowse link
G Hspb1 heat shock protein 1 increases expression ISO Carboplatin results in increased expression of HSPB1 mRNA CTD PMID:18172885 NCBI chr 5:135,887,919...135,889,563
Ensembl chr 5:135,887,919...135,889,563
JBrowse link
G Igf2r insulin-like growth factor 2 receptor decreases expression ISO Carboplatin results in decreased expression of IGF2R mRNA CTD PMID:18172885 NCBI chr17:12,682,406...12,769,706
Ensembl chr17:12,682,406...12,769,664
JBrowse link
G Il6 interleukin 6 decreases response to substance ISO IL6 protein results in decreased susceptibility to Carboplatin CTD PMID:7834629 NCBI chr 5:30,013,114...30,019,975
Ensembl chr 5:30,013,114...30,019,981
JBrowse link
G Il6ra interleukin 6 receptor, alpha decreases response to substance ISO IL6R protein results in decreased susceptibility to Carboplatin CTD PMID:7834629 NCBI chr 3:89,869,324...89,913,196
Ensembl chr 3:89,864,059...89,913,196
JBrowse link
G Jun jun proto-oncogene decreases expression ISO Carboplatin results in decreased expression of JUN mRNA CTD PMID:18172885 NCBI chr 4:95,049,036...95,052,222
Ensembl chr 4:95,049,034...95,052,222
JBrowse link
G Map3k1 mitogen-activated protein kinase kinase kinase 1 decreases expression ISO Carboplatin results in decreased expression of MAP3K1 mRNA CTD PMID:18172885 NCBI chr13:111,746,428...111,818,269
Ensembl chr13:111,746,428...111,808,993
JBrowse link
G Map3k12 mitogen-activated protein kinase kinase kinase 12 decreases expression ISO Carboplatin results in decreased expression of MAP3K12 mRNA CTD PMID:18172885 NCBI chr15:102,497,647...102,517,004
Ensembl chr15:102,497,646...102,517,064
JBrowse link
G Mapk14 mitogen-activated protein kinase 14 decreases expression ISO Carboplatin results in decreased expression of MAPK14 mRNA CTD PMID:18172885 NCBI chr17:28,691,342...28,748,405
Ensembl chr17:28,691,329...28,748,406
JBrowse link
G Mapk6 mitogen-activated protein kinase 6 decreases expression ISO Carboplatin results in decreased expression of MAPK6 mRNA CTD PMID:18172885 NCBI chr 9:75,386,782...75,410,016
Ensembl chr 9:75,369,062...75,410,005
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase decreases expression ISO Carboplatin results in decreased expression of MGMT mRNA CTD PMID:18172885 NCBI chr 7:136,894,463...137,128,193
Ensembl chr 7:136,894,614...137,130,266
JBrowse link
G Mir155 microRNA 155 multiple interactions ISO [Carboplatin co-treated with Chloroquine] results in increased expression of MIR155 mRNA CTD PMID:27692344 NCBI chr16:84,714,140...84,714,204
Ensembl chr16:84,714,140...84,714,204
JBrowse link
G Mir495 microRNA 495 multiple interactions ISO [MIR495 mRNA results in decreased expression of ATP7A protein] which results in increased susceptibility to Carboplatin CTD PMID:24038379 NCBI chr12:109,718,754...109,718,816
Ensembl chr12:109,718,754...109,718,816
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO [Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein CTD PMID:18852009 NCBI chr11:87,793,784...87,804,412
Ensembl chr11:87,793,581...87,804,413
JBrowse link
G Msh2 mutS homolog 2 decreases expression ISO Carboplatin results in decreased expression of MSH2 mRNA CTD PMID:18172885 NCBI chr17:87,672,532...87,723,713
Ensembl chr17:87,672,330...87,723,713
JBrowse link
G Mt1 metallothionein 1 decreases expression ISO Carboplatin results in decreased expression of MT1A mRNA CTD PMID:18172885 NCBI chr 8:94,178,883...94,180,327
Ensembl chr 8:94,179,082...94,180,327
JBrowse link
G Myc myelocytomatosis oncogene increases response to substance ISO MYC protein results in increased susceptibility to Carboplatin CTD PMID:21324178 NCBI chr15:61,985,341...61,990,361
Ensembl chr15:61,985,391...61,990,374
JBrowse link
G Nanog Nanog homeobox increases expression ISO Carboplatin results in increased expression of NANOG mRNA CTD PMID:25605917 NCBI chr 6:122,707,489...122,714,633
Ensembl chr 6:122,707,489...122,714,633
JBrowse link
G Nbas neuroblastoma amplified sequence affects response to substance ISO NBAS intron polymorphism affects the susceptibility to Carboplatin CTD PMID:21844884 NCBI chr12:13,269,101...13,637,380
Ensembl chr12:13,269,133...13,583,811
JBrowse link
G Nckap1 NCK-associated protein 1 decreases expression ISO Carboplatin results in decreased expression of NCKAP1 mRNA CTD PMID:18172885 NCBI chr 2:80,500,512...80,581,182
Ensembl chr 2:80,500,512...80,581,380
JBrowse link
G Nfatc4 nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 4 multiple interactions
increases activity
EXP
ISO
HMOX1 protein inhibits the reaction [Carboplatin results in increased activity of NFATC4] CTD PMID:21198546 NCBI chr14:55,824,795...55,833,943
Ensembl chr14:55,823,144...55,833,943
JBrowse link
G Nfkb1 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 multiple interactions
decreases expression
ISO Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]
Carboplatin results in decreased expression of NFKB1 mRNA
CTD PMID:12675310 PMID:18172885 NCBI chr 3:135,584,655...135,691,969
Ensembl chr 3:135,584,655...135,691,547
JBrowse link
G Nfkbia nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha decreases phosphorylation
multiple interactions
ISO Carboplatin results in decreased phosphorylation of NFKBIA protein
NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]]
CTD PMID:12675310 PMID:15120608 NCBI chr12:55,489,409...55,492,647
Ensembl chr12:55,489,410...55,492,647
JBrowse link
G Nodal nodal increases response to substance ISO NODAL results in increased susceptibility to Carboplatin CTD PMID:21224400 NCBI chr10:61,417,972...61,425,338
Ensembl chr10:61,417,972...61,425,338
JBrowse link
G Nqo1 NAD(P)H dehydrogenase, quinone 1 increases expression ISO Carboplatin results in increased expression of NQO1 mRNA CTD PMID:18172885 NCBI chr 8:107,388,225...107,403,205
Ensembl chr 8:107,388,225...107,403,206
JBrowse link
G Nras neuroblastoma ras oncogene decreases expression ISO Carboplatin results in decreased expression of NRAS mRNA CTD PMID:18172885 NCBI chr 3:103,058,285...103,067,914
Ensembl chr 3:103,058,285...103,067,914
JBrowse link
G Olfr1428 olfactory receptor 1428 affects response to substance ISO OR4D6 gene SNP affects the susceptibility to Carboplatin CTD PMID:26378035 NCBI chr19:12,108,600...12,115,828
Ensembl chr19:12,107,716...12,115,897
JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 increases cleavage ISO Carboplatin results in increased cleavage of PARP1 protein CTD PMID:15996812 NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254
JBrowse link
G Pawr PRKC, apoptosis, WT1, regulator decreases expression ISO Carboplatin results in decreased expression of PAWR mRNA CTD PMID:18172885 NCBI chr10:108,332,189...108,414,391
Ensembl chr10:108,332,121...108,414,240
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions
increases expression
ISO PCNA mRNA affects the reaction [DPYD mRNA affects the susceptibility to Carboplatin]; PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin]
Carboplatin results in increased expression of PCNA mRNA
CTD PMID:16685392 PMID:18172885 NCBI chr 2:132,249,286...132,253,180
Ensembl chr 2:132,249,162...132,253,314
JBrowse link
G Pdcd1lg2 programmed cell death 1 ligand 2 decreases expression
multiple interactions
ISO
EXP
Carboplatin results in decreased expression of PDCD1LG2
STAT6 gene mutant form inhibits the reaction [Carboplatin results in decreased expression of PDCD1LG2]
CTD PMID:21765211 NCBI chr19:29,410,919...29,472,927
Ensembl chr19:29,410,919...29,471,161
JBrowse link
G Pdia4 protein disulfide isomerase associated 4 decreases expression ISO Carboplatin results in decreased expression of PDIA4 mRNA CTD PMID:18172885 NCBI chr 6:47,796,141...47,813,512
Ensembl chr 6:47,796,141...47,813,430
JBrowse link
G Pdia6 protein disulfide isomerase associated 6 decreases expression ISO Carboplatin results in decreased expression of PDIA6 mRNA CTD PMID:18172885 NCBI chr12:17,266,589...17,284,785
Ensembl chr12:17,266,545...17,284,770
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 increases expression ISO Carboplatin results in increased expression of PMAIP1 protein CTD PMID:20802529 NCBI chr18:66,458,604...66,465,558
Ensembl chr18:66,458,533...66,465,565
JBrowse link
G Psmb2 proteasome (prosome, macropain) subunit, beta type 2 increases expression ISO Carboplatin results in increased expression of PSMB2 mRNA CTD PMID:18172885 NCBI chr 4:126,677,637...126,709,715
Ensembl chr 4:126,677,630...126,709,714
JBrowse link
G Psmb4 proteasome (prosome, macropain) subunit, beta type 4 decreases expression ISO Carboplatin results in decreased expression of PSMB4 mRNA CTD PMID:18172885 NCBI chr 3:94,884,324...94,886,958
Ensembl chr 3:94,884,093...94,886,961
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases response to substance
multiple interactions
ISO PTGS2 protein results in decreased susceptibility to Carboplatin
wortmannin inhibits the reaction [PTGS2 protein results in decreased susceptibility to Carboplatin]
CTD PMID:18089846 NCBI chr 1:150,100,031...150,108,234
Ensembl chr 1:150,100,031...150,108,227
JBrowse link
G Rab10 RAB10, member RAS oncogene family decreases expression ISO Carboplatin results in decreased expression of RAB10 mRNA CTD PMID:18172885 NCBI chr12:3,247,428...3,309,969
Ensembl chr12:3,247,428...3,309,969
JBrowse link
G Rbm17 RNA binding motif protein 17 decreases response to substance ISO RBM17 protein results in decreased susceptibility to Carboplatin CTD PMID:16061639 NCBI chr 2:11,585,439...11,603,199
Ensembl chr 2:11,585,437...11,604,153
JBrowse link
G Rela v-rel reticuloendotheliosis viral oncogene homolog A (avian) multiple interactions ISO Carboplatin results in decreased localization of and results in decreased activity of RELA protein; Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]; NFKBIA gene mutant form inhibits the reaction [Carboplatin results in increased activity of [NFKB1 protein binds to RELA protein]] CTD PMID:12675310 PMID:15120608 NCBI chr19:5,637,442...5,648,134
Ensembl chr19:5,637,483...5,648,130
JBrowse link
G Scd2 stearoyl-Coenzyme A desaturase 2 decreases expression ISO Carboplatin results in decreased expression of SCD2 mRNA CTD PMID:18172885 NCBI chr19:44,293,676...44,306,864
Ensembl chr19:44,293,674...44,306,864
JBrowse link
G Sik1 salt inducible kinase 1 increases response to substance ISO SIK1 results in increased susceptibility to Carboplatin CTD PMID:21755009 NCBI chr17:31,844,248...31,855,804
Ensembl chr17:31,844,250...31,855,804
JBrowse link
G Slc31a1 solute carrier family 31, member 1 decreases response to substance
multiple interactions
increases import
increases uptake
increases response to substance
EXP
ISO
SLC31A1 gene mutant form results in decreased susceptibility to Carboplatin
[Penicillamine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [tetrathiomolybdate results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin; [Trientine results in increased expression of SLC31A1 mRNA] which results in increased susceptibility to Carboplatin
SLC31A1 protein results in increased import of Carboplatin
SLC31A1 protein results in increased uptake of Carboplatin
SLC31A1 protein results in increased susceptibility to Carboplatin
CTD PMID:15634647 PMID:16847145 PMID:19509135 PMID:22914438 PMID:23123662 NCBI chr 4:62,360,583...62,391,769
Ensembl chr 4:62,360,727...62,391,769
JBrowse link
G Slc31a2 solute carrier family 31, member 2 decreases uptake EXP SLC31A2 protein results in decreased uptake of Carboplatin CTD PMID:19509135 NCBI chr 4:62,280,393...62,298,412
Ensembl chr 4:62,262,562...62,298,411
JBrowse link
G Smo smoothened, frizzled class receptor increases expression ISO Carboplatin results in increased expression of SMO mRNA CTD PMID:25605917 NCBI chr 6:29,735,497...29,761,366
Ensembl chr 6:29,735,503...29,761,365
JBrowse link
G Sod1 superoxide dismutase 1, soluble multiple interactions
decreases expression
ISO Carboplatin results in decreased expression of and results in decreased activity of SOD1 protein
Carboplatin results in decreased expression of SOD1 protein
CTD PMID:15109710 PMID:15225673 NCBI chr16:90,220,762...90,226,333
Ensembl chr16:90,220,754...90,226,329
JBrowse link
G Sod2 superoxide dismutase 2, mitochondrial multiple interactions
decreases expression
ISO Carboplatin results in increased expression of and results in increased activity of SOD2 protein
Carboplatin results in decreased expression of SOD2 protein
CTD PMID:15109710 PMID:15225673 NCBI chr17:13,007,839...13,018,119
Ensembl chr17:13,006,846...13,040,063
JBrowse link
G Sox2 SRY (sex determining region Y)-box 2 increases expression ISO Carboplatin results in increased expression of SOX2 mRNA CTD PMID:25605917 NCBI chr 3:34,649,995...34,652,461
Ensembl chr 3:34,650,405...34,652,461
JBrowse link
G Stat6 signal transducer and activator of transcription 6 multiple interactions EXP STAT6 gene mutant form inhibits the reaction [Carboplatin results in decreased expression of PDCD1LG2] CTD PMID:21765211 NCBI chr10:127,642,955...127,660,987
Ensembl chr10:127,642,986...127,660,957
JBrowse link
G Stk39 serine/threonine kinase 39 decreases expression ISO Carboplatin results in decreased expression of STK39 mRNA CTD PMID:18172885 NCBI chr 2:68,210,445...68,472,108
Ensembl chr 2:68,210,445...68,472,268
JBrowse link
G Stx2 syntaxin 2 increases response to substance ISO STX2 protein results in increased susceptibility to Carboplatin CTD PMID:24039787 NCBI chr 5:128,984,557...129,008,600
Ensembl chr 5:128,984,557...129,008,574
JBrowse link
G Tfap2a transcription factor AP-2, alpha increases response to substance ISO TFAP2A protein results in increased susceptibility to Carboplatin CTD PMID:16204029 NCBI chr13:40,713,802...40,738,238
Ensembl chr13:40,715,302...40,738,376
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein CTD PMID:18852009 NCBI chr17:35,199,367...35,202,007
Ensembl chr17:35,199,381...35,202,007
JBrowse link
G Top2a topoisomerase (DNA) II alpha multiple interactions ISO TOP2A results in decreased susceptibility to [Carboplatin co-treated with Etoposide co-treated with Ifosfamide] CTD PMID:11325482 NCBI chr11:98,992,947...99,024,199
Ensembl chr11:98,992,943...99,024,189
JBrowse link
G Trp53 transformation related protein 53 increases expression ISO Carboplatin results in increased expression of TP53 protein CTD PMID:9664115 PMID:15131059 NCBI chr11:69,580,348...69,591,873
Ensembl chr11:69,580,359...69,591,873
JBrowse link
G Tyms thymidylate synthase multiple interactions ISO PCNA mRNA affects the reaction [TYMS mRNA affects the susceptibility to Carboplatin] CTD PMID:16685392 NCBI chr 5:30,038,546...30,073,645
Ensembl chr 5:30,058,202...30,073,617
JBrowse link
G Ugt1a6b UDP glucuronosyltransferase 1 family, polypeptide A6B decreases expression ISO Carboplatin results in decreased expression of UGT1A6 mRNA CTD PMID:18172885 NCBI chr 1:88,103,257...88,218,998
Ensembl chr 1:88,103,252...88,219,003
JBrowse link
G Vim vimentin decreases expression ISO Carboplatin results in decreased expression of VIM mRNA CTD PMID:18172885 NCBI chr 2:13,574,311...13,582,826
Ensembl chr 2:13,573,927...13,582,826
JBrowse link
G Xdh xanthine dehydrogenase affects activity ISO Carboplatin affects the activity of XDH protein CTD PMID:15225673 NCBI chr17:73,883,895...73,950,397
Ensembl chr17:73,883,895...73,950,196
JBrowse link
G Xpc xeroderma pigmentosum, complementation group C decreases response to substance EXP XPC results in decreased susceptibility to Carboplatin CTD PMID:19372135 NCBI chr 6:91,489,305...91,515,888
Ensembl chr 6:91,489,305...91,515,888
JBrowse link
G Zfp36l1 zinc finger protein 36, C3H type-like 1 decreases expression ISO Carboplatin results in decreased expression of ZFP36L1 mRNA CTD PMID:18172885 NCBI chr12:80,107,760...80,113,013
Ensembl chr12:80,107,754...80,113,013
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 21545
    chemical entity 21543
      group 21402
        polyatomic entity 21402
          molecule 21025
            cyclic compound 20565
              organic cyclic compound 20564
                carbocyclic compound 19170
                  cyclobutanes 120
                    1-AMINOCYCLOBUTANECARBOXLIC ACID 0
                    3-ETHYLAMINO-4-METHYLAMINO-CYCLOBUTANE-1,2-DIONE 0
                    3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol 0
                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(1S,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                    N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                    N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6R,9R)-8-(cyclobutanecarbonyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                    N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    Pipercyclobutanamide A(rel) 0
                    cis-1,2-Diphenylcyclobutane 0
                    cyclobutane + 0
                    cyclobutanecarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester 0
                    cyclobutanedicarboxylate + 119
                    cyclobutanedicarboxylic acid + 0
                    cyclobutrifluram 0
                    octafluorocyclobutane 0
                    trans-1,2-Diphenylcyclobutane 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 21545
    subatomic particle 21530
      composite particle 21530
        hadron 21530
          baryon 21530
            nucleon 21530
              atomic nucleus 21530
                atom 21530
                  main group element atom 21434
                    p-block element atom 21434
                      p-block molecular entity 21433
                        carbon group molecular entity 21224
                          organic molecular entity 21121
                            organic molecule 21013
                              organic cyclic compound 20564
                                carbocyclic compound 19170
                                  cyclobutanes 120
                                    1-AMINOCYCLOBUTANECARBOXLIC ACID 0
                                    3-ETHYLAMINO-4-METHYLAMINO-CYCLOBUTANE-1,2-DIONE 0
                                    3-[8-amino-1-(2-phenyl-7-quinolinyl)-3-imidazo[1,5-a]pyrazinyl]-1-methyl-1-cyclobutanol 0
                                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aS,9aR)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3R,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-3-[2-(cyclopentylamino)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aR,9aS)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-phenylethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(2-pyridinylmethylamino)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(1S,3S,4aS,9aR)-3-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                                    N-[(2R,3S)-1-((2S)-2-\{[(cyclopentylamino)carbonyl]amino\}-3-methylbutanoyl)-2-(1-formylcyclobutan-1-yl)pyrrolidin-3-yl]cyclopropanecarboxamide 0
                                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[(3-methoxyphenyl)methylamino]-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[(2-pyridin-4-ylacetyl)amino]ethyl]oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[(1-oxo-2-pyridin-4-ylethyl)amino]ethyl]-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]cyclobutanecarboxamide 0
                                    N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6R,9R)-8-(cyclobutanecarbonyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                                    N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclobutanecarboxamide 0
                                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(phenylmethyl)sulfonylamino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                    Pipercyclobutanamide A(rel) 0
                                    cis-1,2-Diphenylcyclobutane 0
                                    cyclobutane + 0
                                    cyclobutanecarboxylic acid 4-[[5-(1-naphthalenyl)-1,3,4-oxadiazol-2-yl]thio]but-2-ynyl ester 0
                                    cyclobutanedicarboxylate + 119
                                    cyclobutanedicarboxylic acid + 0
                                    cyclobutrifluram 0
                                    octafluorocyclobutane 0
                                    trans-1,2-Diphenylcyclobutane 0
paths to the root